Company 3D Medicines Inc.

Equities

1244

KYG8872R1011

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Delayed Hong Kong S.E. Other stock markets 07:44:26 20/05/2024 am IST			5-day change	1st Jan Change
7.82 ^HKD	+4.13%		+20.25%	+2.62%

29/03	3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12%	MT
28/03	3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

3D Medicines Biotechnology Shanghai Co Ltd is a China-based company mainly engaged in the research and development of commercial tumor products and candidate drugs. The Company's main product pipelines including an immuno-oncology monotherapy, drug candidates with mechanisms of action amenable to combination within the pipeline, and pain management assets. The Company's core product is subcutaneous injection of anti-PD-L1, envafolimab. The Company also has a number of candidate drugs in clinical stage, including peptide cancer vaccine 3D189, GAS6 decoy receptor 3D229, fibroblast growth factor receptor (FGFR) 3D185 and others. The Company mainly conducts its business in the domestic market.

Number of employees: 198

HKD in Million	2022	Weight	2023	Weight	Delta
Biopharmaceutical Research and Development 100.0 %	660	100.0 %	702	100.0 %	+6.34%

HKD in Million	2022	Weight	2023	Weight	Delta
China 100.0 %	660	100.0 %	702	100.0 %	+6.34%

Managers	Title	Age	Since
Zhao Long Gong CEO	Chief Executive Officer	60	01/14/01
Jing Zhang DFI	Director of Finance/CFO	50	28/20/28
Zhi Qiang Xue CTO	Chief Tech/Sci/R&D Officer	-	-
Ming Zhu CTO	Chief Tech/Sci/R&D Officer	-	-
Shen Xiao CTO	Chief Tech/Sci/R&D Officer	-	01/21/01
Fang Xia IRO	Public Communications Contact	43	01/20/01
Yue He PRN	Corporate Officer/Principal	46	01/19/01
Yihui Lin PRN	Corporate Officer/Principal	44	30/18/30
Ching Yi Li SEC	Corporate Secretary	-	25/21/25

Members of the board	Title	Age	Since
Tat Pang Lin BRD	Director/Board Member	67	01/22/01
Xin Guang Liu BRD	Director/Board Member	63	25/21/25
Zhao Long Gong CEO	Chief Executive Officer	60	01/14/01
Jin Li BRD	Director/Board Member	59	25/21/25
Pai Zhu BRD	Director/Board Member	31	23/21/23
Feng Zhou BRD	Director/Board Member	42	09/19/09
Yawen Chen BRD	Director/Board Member	32	12/22/12

Name	Equities	%	Valuation
Zhao Long Gong 13.94 %	35,992,364	13.94 %	30 M $
SIMCERE PHARMACEUTICAL GROUP LIMITED 8.926 %	23,047,468	8.926 %	19 M $
Immunal Medixin Us Ltd. 7.414 %	19,143,360	7.414 %	16 M $
Zhenlu Enterprise Management Consulting Partnership 5.328 %	13,758,381	5.328 %	12 M $
E Fund Asset Management Co. Ltd. 0.0792 %	204,500	0.0792 %	171 001 $
Penghua Fund Management Co., Ltd. 0.0622 %	160,500	0.0622 %	134 208 $
China Asset Management (Hong Kong) Ltd. 0.0551 %	142,252	0.0551 %	118 950 $
Yinhua Fund Management Co., Ltd. 0.009489 %	24,500	0.009489 %	20 487 $
Feng Zhou 0.007746 %	20,000	0.007746 %	16 724 $
China Asset Management Co., Ltd. 0.006197 %	16,000	0.006197 %	13 379 $

3D Medicines, Inc.

118 Furong Hua Road Building 11

, Shanghai

http://www.3d-medicines.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
3D MEDICINES INC.	+2.62%	218M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs